Travere Therapeutics, Inc. (NASDAQ:TVTX) – Equities research analysts at William Blair reduced their FY2021 earnings per share estimates for Travere Therapeutics in a report issued on Monday, January 10th. William Blair analyst T. Lugo now expects that the company will post earnings per share of ($2.92) for the year, down from their previous estimate of ($2.74). William Blair also issued estimates for Travere Therapeutics’ Q4 2021 earnings at ($0.75) EPS and FY2022 earnings at ($3.25) EPS.
Other equities analysts have also issued reports about the company. Barclays increased their price objective on Travere Therapeutics from $36.00 to $40.00 and gave the stock an “overweight” rating in a report on Thursday, December 16th. SVB Leerink increased their price objective on Travere Therapeutics from $37.00 to $42.00 and gave the stock an “outperform” rating in a report on Thursday, December 16th. decreased their price target on Travere Therapeutics from $45.00 to $42.00 and set a “buy” rating for the company in a research note on Friday, September 17th. Finally, Zacks Investment Research lowered Travere Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday. One analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. According to MarketBeat, Travere Therapeutics has an average rating of “Buy” and a consensus price target of $31.43.
Travere Therapeutics (NASDAQ:TVTX) last posted its earnings results on Thursday, October 28th. The company reported ($0.59) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.72) by $0.13. The company had revenue of $68.20 million during the quarter, compared to analyst estimates of $60.93 million. Travere Therapeutics had a negative return on equity of 82.45% and a negative net margin of 113.07%. The business’s revenue was up 33.5% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.44) earnings per share.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Advisor Group Holdings Inc. increased its stake in shares of Travere Therapeutics by 1,448.0% in the third quarter. Advisor Group Holdings Inc. now owns 1,161 shares of the company’s stock worth $28,000 after acquiring an additional 1,086 shares during the last quarter. Lindbrook Capital LLC acquired a new position in Travere Therapeutics during the third quarter worth $36,000. Nisa Investment Advisors LLC increased its position in Travere Therapeutics by 45.0% during the third quarter. Nisa Investment Advisors LLC now owns 3,220 shares of the company’s stock worth $78,000 after buying an additional 1,000 shares during the last quarter. Royal Bank of Canada increased its position in Travere Therapeutics by 132.7% during the second quarter. Royal Bank of Canada now owns 4,053 shares of the company’s stock worth $59,000 after buying an additional 2,311 shares during the last quarter. Finally, Teacher Retirement System of Texas acquired a new position in Travere Therapeutics during the third quarter worth $202,000.
In other news, CEO Eric M. Dube sold 4,832 shares of the stock in a transaction on Tuesday, January 4th. The stock was sold at an average price of $30.43, for a total value of $147,037.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Laura Clague sold 7,500 shares of the stock in a transaction on Tuesday, January 11th. The shares were sold at an average price of $27.40, for a total value of $205,500.00. The disclosure for this sale can be found here. Insiders have sold a total of 59,132 shares of company stock valued at $1,686,440 in the last quarter. Insiders own 4.31% of the company’s stock.
About Travere Therapeutics
Travere Therapeutics, Inc is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm’s products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.
See Also: Treasury Bonds
Receive News & Ratings for Travere Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Travere Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.